Addyi vs Vyleesi: Head-to-Head Efficacy for HSDD

Why These Are the Only Two FDA-Approved HSDD Drugs

Flibanserin received FDA approval in August 2015 after three failed attempts and a contentious advisory committee process. Bremelanotide followed in June 2019. Together, they remain the only two medications specifically approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women. No drug is approved for postmenopausal HSDD or for male HSDD as of this writing.

The FDA defines HSDD as a persistent deficit in sexual desire that causes marked personal distress, not explained by another medical or psychiatric condition, a relationship problem, or a substance [1]. Both drugs were evaluated against this definition using co-primary endpoints: the number of satisfying sexual events per month and scores on validated desire instruments such as the Female Sexual Function Index (FSFI) desire domain and the Female Sexual Distress Scale-Revised (FSDS-R) [2][3]. Because the two drugs were tested in separate programs with different placebo-response rates and patient populations, comparing their raw efficacy numbers requires caution. Cross-trial comparisons can suggest relative magnitude, but they cannot replace a randomized head-to-head study.

How Flibanserin Works: Mechanism and Clinical Data

Flibanserin is a 5-HT1A receptor agonist and 5-HT2A receptor antagonist that also weakly antagonizes dopamine D4 receptors. It modulates serotonin and dopamine activity in cortical and subcortical circuits associated with sexual motivation [4]. The drug is taken as a 100 mg tablet every night at bedtime. Its effects accumulate over weeks; the FDA label advises discontinuation after 8 weeks if the patient reports no improvement.

The key evidence comes from three phase III trials. The BEGONIA trial (N=1,087) randomized premenopausal women with HSDD to flibanserin 100 mg or placebo nightly for 24 weeks [2]. Women receiving flibanserin reported a mean increase of 2.5 SSEs per month from baseline, compared with 1.7 for placebo, a treatment difference of roughly 0.8 additional SSEs per month (P<0.01). FSFI desire domain scores improved by 0.7 points more than placebo. The FSDS-R Item 13 (distress about low desire) dropped significantly more in the flibanserin group.

Two additional trials, DAISY and VIOLET, produced consistent results, with SSE differences ranging from 0.5 to 1.0 events per month over placebo [4]. Pooled analyses across all three trials (N=2,400+) confirmed a statistically significant but numerically modest benefit. The FDA's own review noted that the clinical meaningfulness of approximately one-half to one additional SSE per month was debated [5].

Common adverse events with flibanserin include dizziness (11%), somnolence (11%), and nausea (10%). These are why bedtime dosing is mandatory. The boxed warning against concurrent alcohol use reflects the drug's capacity to cause severe hypotension and syncope when combined with ethanol, a concern validated by a pharmacokinetic interaction study in which 25 of 25 subjects showed clinically meaningful blood pressure drops [5].

How Bremelanotide Works: Mechanism and Clinical Data

Bremelanotide is a melanocortin-4 receptor (MC4R) agonist. It activates pathways in the hypothalamus linked to sexual arousal and motivation [6]. Unlike flibanserin's daily regimen, bremelanotide is self-administered as a 1.75 mg subcutaneous injection in the abdomen or thigh at least 45 minutes before anticipated sexual activity. The prescribing information recommends no more than one dose in 24 hours and no more than 8 doses per month.

The RECONNECT program comprised two identically designed phase III trials (Study 301 and Study 302, combined N=1,247) in premenopausal women with HSDD [3]. Over 24 weeks, bremelanotide-treated patients experienced a mean increase of approximately 1.6 SSEs per month from baseline versus 1.1 for placebo, yielding a treatment difference of about 0.5 SSEs per month (P=0.0002 in Study 301). The FSDS-R desire item improved by roughly 0.7 points more than placebo. The co-primary desire endpoint (eDiary desire score) showed a statistically significant but small improvement in Study 301; Study 302 narrowly missed statistical significance on this endpoint, though the SSE and distress endpoints were met in both studies [3].

Nausea is the dominant tolerability concern. In the RECONNECT trials, 40% of bremelanotide-treated patients reported nausea versus 1% on placebo [3]. Most nausea episodes were mild to moderate and decreased with repeated dosing; roughly 90% of nausea events resolved within 2 hours. Still, nausea was the leading reason for discontinuation (7.8% of the bremelanotide group). Flushing (20%), headache (11%), and injection-site reactions (6%) were also more common than placebo. Bremelanotide carries no alcohol restriction.

An important safety signal: bremelanotide transiently raises blood pressure by 2 to 3 mmHg systolic and reduces heart rate modestly [6]. The FDA label contraindicates it in women with uncontrolled hypertension or known cardiovascular disease. A skin-darkening effect (focal hyperpigmentation of the face, gingiva, and breasts) occurred in up to 1% of patients and was generally reversible after discontinuation.

Cross-Trial Efficacy: Putting the Numbers Side by Side

No randomized head-to-head trial has directly compared flibanserin with bremelanotide. That fact is the single most important caveat in any comparison. The numbers below come from separate programs with separate placebo groups and should be interpreted with that limitation in mind.

| Outcome | Flibanserin (BEGONIA) | Bremelanotide (RECONNECT) | |---|---|---| | SSE increase vs. Placebo/month | ~0.8 | ~0.5 | | FSDS-R desire item improvement vs. Placebo | ~0.4 to 0.7 points | ~0.7 points | | FSFI desire domain improvement vs. Placebo | ~0.7 points | ~0.4 to 0.5 points | | Time to onset | 4 to 8 weeks (daily dosing) | 45+ minutes (per-dose onset) | | Treatment duration in key trial | 24 weeks | 24 weeks |

The placebo SSE rate differed between programs: BEGONIA's placebo arm gained 1.7 SSEs/month, while RECONNECT's placebo arm gained approximately 1.1 SSEs/month. Higher placebo responses can compress the apparent drug-placebo gap. A 2020 network meta-analysis published in The Journal of Sexual Medicine attempted to place both drugs on a common scale and concluded that the two were "broadly similar" in efficacy, with overlapping confidence intervals for SSE improvement and desire scores [7]. The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction lists both agents as options for HSDD without expressing a preference for one over the other [8].

Dr. Sheryl Kingsberg, a lead investigator on both the flibanserin and bremelanotide programs, stated in a 2019 interview with Ob.Gyn. News: "These drugs give us two mechanistically distinct options. The right choice depends on the woman's lifestyle, her relationship to daily medication, and her side-effect priorities."

Side-Effect Profiles Compared

The side-effect profiles diverge enough that they often drive the clinical decision more than efficacy numbers do.

Flibanserin's main burden is central nervous system depression: dizziness and sleepiness that mandate bedtime dosing. The alcohol interaction is a practical dealbreaker for some patients. Women who drink regularly, even moderately, face real risks of hypotension and syncope if they take flibanserin. The FDA initially required a REMS program with prescriber certification, though the agency relaxed this in 2019 by removing the prescriber-enrollment requirement and retaining only the patient-prescriber counseling component [5].

Bremelanotide's main burden is peripheral: nausea in 40% of patients and a needle-based route of administration [3]. The nausea typically attenuates after the first several doses, but early dropout is not uncommon. Women with needle aversion or those who find the injection logistics new may prefer a pill. The cardiovascular caution limits bremelanotide's use in women with hypertension, whereas flibanserin has no specific cardiovascular contraindication (beyond the hypotension risk with alcohol).

Neither drug has demonstrated dependency, withdrawal, or rebound effects in clinical trials up to 18 months [2][3]. Neither drug is a controlled substance.

Daily Pill vs. On-Demand Injection: The Practical Decision

The dosing approach is the sharpest practical difference. A daily oral tablet appeals to women who want a "set and forget" approach to desire, one that doesn't require planning around sexual encounters. Women in this category may also prefer the gradual onset of flibanserin; its effects build over weeks and sustain as long as the medication is continued, without tying desire to a specific act.

An on-demand injection appeals to women who dislike taking a daily medication for a condition they may experience intermittently. Bremelanotide allows targeted use: if a woman anticipates a sexual encounter, she injects 45 minutes to an hour beforehand. This model avoids 365-day drug exposure for events that might occur a few times per month. The trade-off is that each use requires a subcutaneous injection and a window of potential nausea.

Dr. Anita Clayton, former president of the International Society for the Study of Women's Sexual Health, summarized the clinical calculus in a 2021 review: "For the woman who wants background desire restoration, flibanserin makes sense. For the woman who wants situational, event-driven support, bremelanotide fits better" [9].

Cost also factors in. Both drugs are branded with no generic equivalents available as of May 2026. Addyi's list price runs approximately $100 per month for daily dosing. Vyleesi's list price is approximately $900 for a pack of four autoinjectors, translating to roughly $225 per dose at list price, though actual out-of-pocket costs vary widely by insurance and manufacturer coupons [10]. Women using bremelanotide infrequently (2 to 3 times per month) may find the per-month cost comparable to flibanserin, while frequent users face significantly higher expenses.

Who Is a Candidate for Each Drug?

Both drugs are FDA-approved only for premenopausal women with acquired, generalized HSDD. They are not approved for postmenopausal women, for men, or for women whose low desire is situational (partner-specific) or attributable to another medical condition, medication side effect, or substance use [5][6].

Flibanserin may be a better fit for women who prefer oral dosing, do not drink alcohol or drink very rarely, tolerate mild sedation well, and want a continuous effect on baseline desire. It should be avoided in women taking strong or moderate CYP3A4 inhibitors (fluconazole, ketoconazole, certain HIV protease inhibitors), which dramatically increase flibanserin plasma levels and hypotension risk [5].

Bremelanotide may be a better fit for women who prefer on-demand dosing, drink alcohol socially and do not want restrictions, are comfortable with subcutaneous injections, and whose HSDD symptoms are intermittent enough to manage with event-driven therapy. It should be avoided in women with uncontrolled hypertension or cardiovascular disease, and caution is warranted in those with hepatic impairment, as bremelanotide exposure increases with liver dysfunction [6].

Neither drug should be prescribed without a thorough biopsychosocial assessment. The ISSWSH process of care algorithm recommends that clinicians screen for contributing factors (depression, relationship conflict, medication side effects, hormonal status) and address modifiable causes before initiating pharmacotherapy [11].

Off-Label and Combination Use: What the Evidence Shows

Some clinicians prescribe both drugs to postmenopausal women off-label. The evidence base for this is thin. A small open-label study of flibanserin in postmenopausal women (N=125) showed improvement in desire and SSEs, but no phase III postmenopausal trial has been completed for either agent [4]. The Endocrine Society guideline explicitly does not recommend either drug for postmenopausal HSDD outside of clinical trials [8].

Combination use (flibanserin daily plus bremelanotide as needed) has no published trial data and carries unknown interaction risks. No pharmacokinetic interaction study has been conducted. Clinicians who consider combination use are operating without a safety net of published evidence.

Testosterone therapy, while not FDA-approved for women in the United States, has a stronger evidence base for postmenopausal HSDD. The ADORE trial and a Lancet meta-analysis (N=8,480 across 46 RCTs) showed that transdermal testosterone at 300 mcg/day significantly improved desire and SSEs in postmenopausal women [12]. This creates a situation where the two FDA-approved drugs target a population (premenopausal) for which the unmet need is real but relatively smaller, while the larger postmenopausal population remains off-label for all pharmacologic options.

Discontinuation, Switching, and Long-Term Data

Discontinuation rates in key trials were notable for both drugs. In the BEGONIA trial, 9.6% of flibanserin patients withdrew due to adverse events compared with 3.7% on placebo [2]. In the RECONNECT program, the adverse event discontinuation rate was 13.2% for bremelanotide versus 1.5% for placebo [3].

Women who fail one drug can reasonably try the other, given the distinct mechanisms. No formal switching study has been published, but the different receptor targets (serotonin/dopamine for flibanserin, melanocortin for bremelanotide) suggest that failure on one does not predict failure on the other. A washout period is prudent but no specific duration is mandated in either label.

Long-term extension studies for both drugs show sustained efficacy through 12 to 18 months without new safety signals [4][6]. Neither drug has demonstrated tachyphylaxis (loss of effect over time) in published data.

Women starting either drug should have a follow-up visit at 8 to 12 weeks to assess response, using the FSDS-R or a simple patient-reported outcome of desire frequency and satisfaction. If benefit is absent at 8 weeks for flibanserin, the FDA label recommends discontinuation [5]. Bremelanotide response can be assessed sooner, given its per-dose action, but a minimum of 4 to 6 uses is reasonable before concluding inadequate response.